In this webinar, Clearstate will be centering the discussion on how the IVD landscape in emerging markets has evolved post-pandemic, new focus areas for growth and the complex environment.

The cancer burden in Asia is increasing, with new cancer cases expected to grow 49% by 2040 compared to 2020.  More patients are undergoing biomarker testing in order to access more targeted and effective therapies. Economist Intelligence Clearstate expects the number of patients undergoing routine molecular testing for cancer biomarkers tracked by IVD Gateway to grow at an average annual rate as high as more than 30% average annual growth from 2021 to 2026 in Asia’s fastest-growing market for the segment.

Japan’s ageing population is catalysing the demand for high-quality orthopaedic treatments. Robot-assisted solutions will play an integral role in supporting surgeons deliver procedures for the country’s “super-aged” society.

China’s wound closure market—covering synthetic, conventional and barbed sutures—grew by more than 20% in 2021 compared to the previous year. This is due to the recovery of surgery procedures and the purchasing of higher-value devices.

China’s advanced energy device market—covering generators, handles and blades—grew by more than 30% in 2021 compared to the previous year. This is due to the recovery of surgery procedures, organic growth in surgery volume and increased uptake of single-use blades.

Gain an understanding of where the opportunities and challenges located deep in Chinese cities lie, with Clearstate’s insight into the size and breadth of domestic penetration in these markets. 

Recovery in surgery volume is driving market growth for general surgery devices in China, with surgery volume growing fastest in Tier 3 and Tier 4 cities, followed by Tier 2 cities. Surgery volume increased by more than 20% in 2021 compared to 2020. Other surgery areas growing at more than 20% in 2021 are orthopaedics, gynaecology and neurological and cardiac surgery.

The impact of China’s latest covid-19 surge heads the latest quarterly in-vitro diagnostics (IVD) market data. Point-of-care (POC) testing for infectious diseases is emerging as the best-performing market segment in Q2 2022, based on the latest data and analysis from Economist Intelligence Clearstate’s Quarterly Company Insights (QCI) for China.

While emerging markets have grown and exceeded their pre-pandemic size, this growth is largely attributed to covid-19 testing. Yet to recover are IVD businesses outside of covid-19 testing in the Middle East and Latin America regions, as well as some countries in Asia-Pacific.

China’s government is investing to build up the country’s in vitro diagnostics (IVD) testing capacity and meet strong clinical demand from an ageing population. With major policies and the growth of domestic players shaking up the country’s IVD market dynamics, companies are localising and adapting their strategies to stay ahead in this fast-evolving market. 

Stay up to date with new insights, trends and forecasts in the in-vitro diagnostics (IVD) and surgical sectors with Clearstate’s curated topics, ranging from point-of-care testing (POCT), molecular diagnostics (MDx), orthopaedic robotic surgery to transcatheter aortic valve replacement.

Clearstate’s IVD Gateway solution delivers precise, credible and granular market data with global forecasts.